Hey Bakersson! You make all really good points. Having your background would be a great asset at MILV.
So, I cant really talk about that type of nitty gritty without pulling out my biochemistry book.
What I can share is that the biologist behind this biotech company is Michael W. Fountain. A professor and researcher for over 45 years in liposomal research at USF.
He has 131 domestic and international patents. He has 180 international products. He has built or been apart of 11 companies, one of which, "The Liposome Company" was bought out by Elan Corp for $575 Million. Later, Elan was bought for $8.6 billion by Perrigo. That was 20 years ago.
In addition, the company with their name change that happened last night to NDT Pharmaceuticals has an open contract with the University of Pennsylvania and Childrens Hospital of Philadelphia to run the research and trials I am expecting you are talking about for different compounds that scientists are testing. I do not know just how much research is currently going on ar UPENN but it has been going on for 4-5 years.
If you please check out ccabiotech.blogspot.com/p/home.html
And read who the major shareholders are, I think you will decide to throw in a couple bucks at MILV.
1. Edward J. Mathias - one of the founders and now senior adviser to "The Carlyle Group" (look them up - $200 bill in assets) AND TRUSTEE EMERITUS TO........? University of Pennsylvania... hmmm
2. Stuart Yarbrough - cofounder of Crosshill Financial Group. They seed small companies with $3 - 50 million and make the companies look good to much larger companies... oh and he has worked with Edward Mathias.
I could go on... there is way more than meets the eye here.
James Hovis has sold preventative and reguvinative medical drink lines -- AQUISS Beverage and AQUIS to. And licensed his patents
